Oct 2026· Asian Journal of Research in Pharmaceutical Sciences· Vol 16, pp. 381· 0 citations· 23 references
TL;DR
The historical and regulatory foundations of QbD are explored, and the core principles, tools, industrial implementations, benefits, challenges, and future directions of QbD in pharmaceutical development are examined.
Abstract
Background: Quality by Design (QbD) is a proactive, science based approach emphasizing systematic risk managed design in pharmaceutical development, moving away from traditional quality by testing methods. Objectives: To explore the historical and regulatory foundations of QbD (particularly ICH Q8–Q11), and to examine the core principles, tools, industrial implementations, benefits, challenges, and future directions of QbD in pharmaceutical development. Methods: Analysis and synthesis of multiple peer reviewed reviews and regulatory documents: including ICH Q8–Q11 guidelines, case studies, risk tools (e.g. FMEA, Ishikawa diagram), design of experiments (DoE), Process Analytical Technology (PAT), and control strategies. Applications and Case Studies: Demonstrated in small molecules, biologics, and advanced delivery systems; QbD enabled case studies have reported improved process understanding, streamlined formulation, robust scale up, faster approvals, and regulatory flexibility. Benefits: Improved quality consistency; enhanced manufacturing efficiency; reduced variability; lower regulatory burden; accelerated time to market; and robust lifecycle control. Challenges: High upfront costs; regulatory complexity and need for clear guidance; cultural and organizational change; data management challenges; and incomplete adoption in routine commercial manufacturing. Future Trends: Integration of digital tools, AI/machine learning, continuous manufacturing, advanced analytics, retrospective QbD, and automation frameworks is expected to further enhance QbD implementation. Conclusion: QbD represents a transformative shift in pharmaceutical development by embedding quality throughout the product lifecycle. While adoption faces hurdles, advances in regulatory alignment and digital innovation are poised to drive broader implementation and enhanced patient safety.
The concept of "Sustainability by Design" (SbD) in the pharmaceutical industry refers to the systematic integration of sustainability principles into products by defining parameters critical to both their quality and environmental protection. Unlike the traditional approach, which considers environmental aspects retros...
Quality by Design (QbD) provides a science- and risk-based framework for developing generic immediate-release (IR) and sustained-release (SR) tablets. Its practical value, however, depends on translating formulation and process knowledge into evidence supporting bioequivalence (BE), manufacturing robustness, and regula...
Sivakumar Thanikachalam· Pharmaceutical development a...· 0 citations
Introduction. The manufacturing of powder dosage forms requires control of the physicochemical and technological characteristics of starting materials, as well as blending, transfer, and dosing parameters. The Quality by Design (QbD) concept provides a scientific and risk-based framework for evaluating factors affectin...
E. Serikbayeva, K. Zhakipbekov, A. Mukanova et al.· Farmaciâ Kazahstana· 0 citations
Quality by Design (QbD), established through the International Council for Harmonisation (ICH) Q8(R2), Q9, and Q10 guidelines, provides a science-based framework for proactive quality assurance. Lean and Six Sigma, collectively referred to as Lean Six Sigma (LSS), offer complementary methodologies for waste elimination...
Revinta Kurnia Septanti, Akbar Adhiutama· Jurnal Locus Penelitian dan...· 0 citations
This study reveals that Türkiye’s pharmaceutical sector faces not only operational but also complex structural and systemic challenges requiring a holistic approach, highlighting the need for a strategic governance framework to boost predictability, strengthen institutional capacity, and ensure long-term financial sust...
Selin Kalender· Yönetim bilimleri dergisi· 0 citations
BACKGROUND
Data integrity (DI) has become a central pillar of pharmaceutical quality assurance and a recurrent focus of regulatory inspections worldwide. Despite mature guidance, DI deficiencies remain among the most frequently cited inspection observations in good-practice (GxP) environments. This systematic review ai...
Meryem Chennaq, Sulikoia Lare, Z. Aliat et al.· Annales Pharmaceutiques Fran...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.